ORIC Pharmaceuticals, Inc.
ORICHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. At a $874.7M market cap, ORIC Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Market Cap
$874.7M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-5.45
EPS (TTM)
$-1.39
EPS (Fwd)
$-1.55
ROE
-42.6%
ROA
-27.6%
Cash
$281.9M
Total Debt
$6.7M
Free CF
-$68.0M
52W Change
-0.2%
Annual Financials
Cash vs Debt
ORIC Pharmaceuticals, Inc. holds $281.9M in cash against $6.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$68.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ORIC Pharmaceuticals, Inc.'s trajectory.